Sosei Heptares is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR technology and structure-based drug design platform capabilities. The Company aims to advance a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications.
|HQ||Chiyoda City, JP||Map|
Market capitalization (14-Sept-2020)
Closing stock price (14-Sept-2020)
|Company Name||Date||Deal Size|
|Heptares Therapeutics||February 22, 2015||$400 m|
Sosei Heptares has 2.1k Twitter Followers. The number of followers has increased 1.1% month over month and increased 7% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Sosei Heptares founded?
Sosei Heptares was founded in 1990.
Who are Sosei Heptares key executives?
Sosei Heptares's key executives are Chris Cargill, Shinichi Tamura and Barry Kenny.
How many employees does Sosei Heptares have?
Sosei Heptares has 170 employees.
Who are Sosei Heptares competitors?
Competitors of Sosei Heptares include LEO Pharma, Imara and Tanvex Biopharma.
Where is Sosei Heptares headquarters?
Sosei Heptares headquarters is located at 2-1 Kojimachi, Chiyoda City.
Where are Sosei Heptares offices?
Sosei Heptares has offices in Chiyoda City, Great Abington and London.
How many offices does Sosei Heptares have?
Sosei Heptares has 3 offices.
Receive alerts for 300+ data fields across thousands of companies